PAPER Neltner JH, Abner EL, Schmitt FA, Denison SK, Anderson S, Patel E, Nelson PT

Digital pathology and image analysis for robust high-throughput quantitative assessment of Alzheimer disease neuropathologic changes.

J Neuropathol Exp Neurol. 2012 Dec;71(12):1075-85. PubMed: 23147505

PAPER Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, Holtzman DM, Wancewicz E, Bennett CF, Bowser R, Cudkowicz M, Miller TM

SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy.

Arch Neurol. 2012 Nov 12;:1-7. PubMed: 23147550

PAPER

Alzheimer disease: Hormone therapy and the risk of AD-timing may be key.

Science. 2013 Jan 18;339(6117):321-4. PubMed: 23147847

PAPER

Alzheimer disease: Cladribine promotes amyloid plaque formation in mice.

Science. 2013 Jan 18;339(6117):321-4. PubMed: 23147852

Michael Heneka on Enter the New Alzheimer’s Gene: TREM2 Variant Triples Risk

COMMENT Triggering receptor expressed on myeloid cells 2 (TREM2) represents a surface receptor without its own intracellular signaling motif. It therefore depends on the adaptor protein 12 (DAP12) for the initiation of signaling cascades. TREM2 has been primarily

PAPER Bouchon A, Dietrich J, Colonna M

Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes.

J Immunol. 2000 May 15;164(10):4991-5. PubMed: 10799849

PAPER Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL

Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12.

J Immunol. 2006 Aug 15;177(4):2051-5. PubMed: 16887962

PAPER Takahashi K, Rochford CD, Neumann H

Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2.

J Exp Med. 2005 Feb 21;201(4):647-57. PubMed: 15728241

PAPER Sessa G, Podini P, Mariani M, Meroni A, Spreafico R, Sinigaglia F, Colonna M, Panina P, Meldolesi J

Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia.

Eur J Neurosci. 2004 Nov;20(10):2617-28. PubMed: 15548205

Bruno Pietro Imbimbo on CTAD: New Data on Sola, Bapi, Spark Theragnostics Debate

COMMENT Soluble β amyloid has a beneficial physiological role for the normal functioning of neurons. In the AD brain, the increase in soluble β amyloid concentrations, mainly via a decrease in its clearance, could simply represent the brain's attempt to medi

Bruno Pietro Imbimbo

Chiesi Farmaceutici S.p.A.
Parma, Italy

Ann Smith

School of Biological Sciences, University of Missouri-Kansas City
Kansas City, United States

Enter the New Alzheimer’s Gene: TREM2 Variant Triples Risk

RESEARCH NEWS 2012-11-14 Research News Rare mutations in a microglial receptor contribute as much to Alzheimer’s risk as does the more common ApoE4 genotype, according to back-to-back papers in the November 14 New England Journal of Medicine online. Variants in the triggering rec

CTAD: ApoE Carriers Sought for Trial of NSAID Derivative

CONFERENCE COVERAGE 2012-11-14 Conference Coverage Updated 29 November 2012 The 5th Clinical Trials in Alzheimer’s Disease conference, held 29-31 October in Monaco, featured a new Phase 2 program that uses genetics to enrich an MCI population for an early-stage therapeutic trial. The d

PAPER Peyer AK, Kinter J, Hench J, Frank S, Fuhr P, Thomann S, Fischmann A, Kneifel S, Camaño P, Munain AL, Sinnreich M, Renaud S

Novel valosin containing protein mutation in a Swiss family with hereditary inclusion body myopathy and dementia.

Neuromuscul Disord. 2013 Feb;23(2):149-54. PubMed: 23140793